FAAH Antibody (27-Y): sc-100739

FAAH Antibody (27-Y) is a mouse monoclonal IgG2a kappa light chain antibody that detects FAAH protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-FAAH antibody (27-Y) is available as the non-conjugated isotype antibody. FAAH protein, or fatty acid amide hydrolase, is a crucial membrane-bound enzyme that plays a significant role in the hydrolysis of various primary and secondary fatty acid amides, including important neuromodulatory compounds such as anandamide and oleamide. The enzymatic degradation of anandamide to arachidonic acid and oleamide to oleic acid is vital for terminating the signaling functions of these bioactive lipids, thereby regulating physiological processes such as pain sensation, mood, and appetite. FAAH exhibits equivalent catalytic efficiency for both amides and esters, allowing FAAH to function effectively as both an amidase and an esterase. This dual functionality is essential for maintaining the balance of lipid signaling in the body. FAAH is involved in the uptake of anandamide by establishing and sustaining an inward concentration gradient, which is critical for its physiological effects. A natural single nucleotide polymorphism in the human FAAH gene, particularly in its homozygous form, has been linked to an increased risk of problem drug use, highlighting FAAH′s importance in addiction biology. The human FAAH gene is located on chromosome 1p33, making FAAH a significant target for research in pharmacogenomics and therapeutic interventions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

FAAH Antibody (27-Y) References:

1. Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism.  |  Patricelli, MP. and Cravatt, BF. 1999. Biochemistry. 38: 14125-30. PMID: 10571985
2. Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide.  |  Day, TA., et al. 2001. Mol Pharmacol. 59: 1369-75. PMID: 11353795
3. A missense mutation in human fatty acid amide hydrolase associated with problem drug use.  |  Sipe, JC., et al. 2002. Proc Natl Acad Sci U S A. 99: 8394-9. PMID: 12060782
4. CNR1 and FAAH variation and affective states induced by marijuana smoking.  |  Palmer, RHC., et al. 2019. Am J Drug Alcohol Abuse. 45: 514-526. PMID: 31184938
5. FAAH levels and its genetic polymorphism association with susceptibility to methamphetamine dependence.  |  Zhang, W., et al. 2020. Ann Hum Genet. 84: 259-270. PMID: 31789429
6. The influence of FAAH genetic variation on physiological, cognitive, and neural signatures of fear acquisition and extinction learning in women with PTSD.  |  Crombie, KM., et al. 2022. Neuroimage Clin. 33: 102922. PMID: 34952353
7. Nitric oxide positively affects endometrial receptivity via FAAH and NAPE-PLD in vitro.  |  Melford, SE., et al. 2021. Reprod Fertil. 2: 107-116. PMID: 35128447
8. A genetic variant of fatty acid amide hydrolase (FAAH) exacerbates hormone-mediated orexigenic feeding in mice.  |  Balsevich, G., et al. 2023. Elife. 12: PMID: 37039453
9. Functional Variation in the FAAH Gene Is Directly Associated with Subjective Well-Being and Indirectly Associated with Problematic Alcohol Use.  |  Bornscheuer, L., et al. 2023. Genes (Basel). 14: PMID: 37761966
10. FAAH inhibition ameliorates breast cancer in a murine model.  |  Tripathy, M., et al. 2023. Oncotarget. 14: 910-918. PMID: 37921652
11. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides.  |  Cravatt, BF., et al. 1996. Nature. 384: 83-7. PMID: 8900284
12. Molecular characterization of human and mouse fatty acid amide hydrolases.  |  Giang, DK. and Cravatt, BF. 1997. Proc Natl Acad Sci U S A. 94: 2238-42. PMID: 9122178

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-FAAH Antibody (27-Y) has 14 citations in a variety of scientific publications.

Primary antibodies like Anti-FAAH Antibody (27-Y) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

FAAH Antibody (27-Y) Specifications

Alternate Product Name: FAAH

Product Clone Name: 27-Y

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 480-580

Epitope Target: FAAH

Epitope Species: human

Product Reactivity/Detection: FAAH

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, ELISA

Vialing Information: Each vial contains 100 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 14 citations in various scientific publications

Available Conjugates/Forms for FAAH Antibody (27-Y): N/A